Literature DB >> 26054047

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Hajime Uno, Janet Wittes, Haoda Fu, Scott D Solomon, Brian Claggett, Lu Tian, Tianxi Cai, Marc A Pfeffer, Scott R Evans, Lee-Jen Wei.   

Abstract

A noninferiority study is often used to investigate whether a treatment's efficacy or safety profile is acceptable compared with an alternative therapy regarding the time to a clinical event. The empirical quantification of the treatment difference for such a study is routinely based on the hazard ratio (HR) estimate. The HR, which is not a relative risk, may be difficult to interpret clinically, especially when the underlying proportional hazards assumption is violated. The precision of the HR estimate depends primarily on the number of observed events but not directly on exposure times or sample size of the study population. If the event rate is low, the study may require an impractically large number of events to ensure that the prespecified noninferiority criterion for the HR is attainable. This article discusses deficiencies in the current approach for the design and analysis of a noninferiority study. Alternative procedures are provided, which do not depend on any model assumption, to compare 2 treatments. For a noninferiority safety study, the patients' exposure times are more clinically important than the observed number of events. If the patients' exposure times are long enough to evaluate safety reliably, then these alternative procedures can effectively provide clinically interpretable evidence on safety, even with relatively few observed events. These procedures are illustrated with data from 2 studies. One explores the cardiovascular safety of a pain medicine; the second examines the cardiovascular safety of a new treatment for diabetes. These alternative strategies to evaluate safety or efficacy of an intervention lead to more meaningful interpretations of the analysis results than the conventional strategy that uses the HR estimate.

Entities:  

Mesh:

Year:  2015        PMID: 26054047      PMCID: PMC4510023          DOI: 10.7326/M14-1741

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  21 in total

1.  Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.

Authors:  Ralph B D'Agostino; Joseph M Massaro; Lisa M Sullivan
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

2.  The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis.

Authors:  L J Wei
Journal:  Stat Med       Date:  1992 Oct-Nov       Impact factor: 2.373

3.  Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Authors:  Scott D Solomon; Marc A Pfeffer; John J V McMurray; Rob Fowler; Peter Finn; Bernard Levin; Craig Eagle; Ernest Hawk; Mariajosé Lechuga; Ann G Zauber; Monica M Bertagnolli; Nadir Arber; Janet Wittes
Journal:  Circulation       Date:  2006-09-05       Impact factor: 29.690

4.  SAS and R functions to compute pseudo-values for censored data regression.

Authors:  John P Klein; Mette Gerster; Per Kragh Andersen; Sergey Tarima; Maja Pohar Perme
Journal:  Comput Methods Programs Biomed       Date:  2008-01-15       Impact factor: 5.428

5.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

6.  Nonparametric estimation for the difference or ratio of median failure times.

Authors:  J Q Su; L J Wei
Journal:  Biometrics       Date:  1993-06       Impact factor: 2.571

7.  The hazards of hazard ratios.

Authors:  Miguel A Hernán
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

8.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

9.  Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs.

Authors:  Boaz Hirshberg; Itamar Raz
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

Review 10.  Through the looking glass: understanding non-inferiority.

Authors:  Jennifer Schumi; Janet T Wittes
Journal:  Trials       Date:  2011-05-03       Impact factor: 2.279

View more
  59 in total

1.  Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.

Authors:  Masayuki Kaneko; Mamoru Narukawa
Journal:  Clin Drug Investig       Date:  2019-02       Impact factor: 2.859

2.  How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

Authors:  Miki Horiguchi; Michael J Hassett; Hajime Uno
Journal:  Oncologist       Date:  2018-09-10

Review 3.  Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.

Authors:  Masayuki Kaneko; Mamoru Narukawa
Journal:  Clin Drug Investig       Date:  2019-05       Impact factor: 2.859

4.  Adjusted restricted mean survival times in observational studies.

Authors:  Sarah C Conner; Lisa M Sullivan; Emelia J Benjamin; Michael P LaValley; Sandro Galea; Ludovic Trinquart
Journal:  Stat Med       Date:  2019-05-22       Impact factor: 2.373

5.  Age Differences in Work-Disability Duration Across Canada: Examining Variations by Follow-Up Time and Context.

Authors:  Jonathan K Fan; Robert A Macpherson; Peter M Smith; M Anne Harris; Monique A M Gignac; Christopher B McLeod
Journal:  J Occup Rehabil       Date:  2021-06

6.  Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.

Authors:  Duy Ngo; Richard Baumgartner; Shahrul Mt-Isa; Dai Feng; Jie Chen; Patrick Schnell
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

7.  Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks.

Authors:  Lihui Zhao; Lu Tian; Brian Claggett; Marc Pfeffer; Dae Hyun Kim; Scott Solomon; Lee-Jen Wei
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

8.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

9.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

10.  Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Martee L Hensley; Danielle Enserro; Helen Hatcher; Petronella B Ottevanger; Anders Krarup-Hansen; Jean-Yves Blay; Cyril Fisher; Katherine M Moxley; Shashikant B Lele; Jayanthi S Lea; Krishnansu S Tewari; Premal H Thaker; Oliver Zivanovic; David M O'Malley; Katina Robison; David S Miller
Journal:  J Clin Oncol       Date:  2018-10-05       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.